Abstract: A nutritional supplement including ?-cryptoxanthin is found to be effective at lowering blood pressure in mammals. ?-cryptoxanthin therefore may be used to maintain cardiovascular health by lowering blood pressure, preventing high, elevated blood pressure and/or maintaining healthy blood pressure. Administration of ?-cryptoxanthin in combination with safflower oil is particularly effective.

Abstract: A nutritional supplement including ?-cryptoxanthin is found to be effective at lowering blood pressure in mammals. ?-cryptoxanthin therefore may be used to maintain cardiovascular health by lowering blood pressure, preventing high, elevated blood pressure and/or maintaining healthy blood pressure. Administration of ?-cryptoxanthin in combination with safflower oil is particularly effective.

Abstract: The present invention relates to a process for converting lutein and/or lutein esters to (3R)-?-cryptoxanthin and (3R,6?R)-?-cryptoxanthin, suitable for human consumption as dietary supplements, by employing safe and environmentally friendly reagents. (3R)-?-Cryptoxanthin and (3R,6?R)-?-cryptoxanthin are two rare food carotenoids that are not commercially available and the former exhibits vitamin A activity. In the first synthetic step, commercially available lutein and/or lutein esters are transformed into a mixture of dehydration products of lutein (anhydroluteins) in the presence of a catalytic amount of an acid. The resulting anhydroluteins are then converted to (3R)-?-cryptoxanthin (major product) and (3R,6?R)-?-cryptoxanthin (minor product) by heterogeneous catalytic hydrogenation employing transition elements of group VIII (Pt, Pd, Rh supported on alumina or carbon) in a variety of organic solvents under atmospheric pressure of hydrogen and at temperatures ranging from ?15° C. to 40° C.

Abstract: A nutritional supplement including ?-cryptoxanthin is found to be effective at lowering blood pressure in mammals. ?-cryptoxanthin therefore may be used to maintain cardiovascular health by lowering blood pressure, preventing high, elevated blood pressure and/or maintaining healthy blood pressure. Administration of ?-cryptoxanthin in combination with safflower oil is particularly effective.

Abstract: The present invention relates to a process for converting lutein and/or lutein esters to (3R)-?-cryptoxanthin and (3R,6?R)-?-cryptoxanthin, suitable for human consumption as dietary supplements, by employing safe and environmentally friendly reagents. (3R)-?-Cryptoxanthin and (3R,6?R)-?-cryptoxanthin are two rare food carotenoids that are not commercially available and the former exhibits vitamin A activity. In the first synthetic step, commercially available lutein and/or lutein esters are transformed into a mixture of dehydration products of lutein (anhydroluteins) in the presence of a catalytic amount of an acid. The resulting anhydroluteins are then converted to (3R)-?-cryptoxanthin (major product) and (3R,6?R)-?-cryptoxanthin (minor product) by heterogeneous catalytic hydrogenation employing transition elements of group VIII (Pt, Pd, Rh supported on alumina or carbon) in a variety of organic solvents under atmospheric pressure of hydrogen and at temperatures ranging from ?15° C. to 40° C.

Abstract: A nutritional supplement including ?-cryptoxanthin is found to be effective at lowering blood pressure in mammals. ?-cryptoxanthin therefore may be used to maintain cardiovascular health by lowering blood pressure, preventing high, elevated blood pressure and/or maintaining healthy blood pressure. Administration of ?-cryptoxanthin in combination with safflower oil is particularly effective.

Abstract: The present invention relates to a process for converting lutein and/or lutein esters to (3R)-?-cryptoxanthin and (3R,6?R)-?-cryptoxanthin, suitable for human consumption as dietary supplements, by employing safe and environmentally friendly reagents. (3R)-?-Cryptoxanthin and (3R,6?R)-?-cryptoxanthin are two rare food carotenoids that are not commercially available and the former exhibits vitamin A activity. In the first synthetic step, commercially available lutein and/or lutein esters are transformed into a mixture of dehydration products of lutein (anhydroluteins) in the presence of a catalytic amount of an acid. The resulting anhydroluteins are then converted to (3R)-?-cryptoxanthin (major product) and (3R,6?R)-?-cryptoxanthin (minor product) by heterogeneous catalytic hydrogenation employing transition elements of group VIII (Pt, Pd, Rh supported on alumina or carbon) in a variety of organic solvents under atmospheric pressure of hydrogen and at temperatures ranging from ?15° C. to 40° C.